A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Dinalbuphine-sebacate (Primary) ; Paracetamol (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Sinew Pharma
- 17 May 2023 Status changed from not yet recruiting to recruiting.
- 09 May 2023 New trial record